Introduction {#S1}
============

Blood lipids are heritable, modifiable, risk factors for coronary artery disease (CAD)^[@R1],[@R2]^, a leading cause of death^[@R3]^. Human genetic studies of lipid levels can identify targets for new therapies for cholesterol management and prevention of heart disease, and can complement animal studies^[@R4],[@R5]^. Studies of naturally occurring genetic variation can proceed through large-scale association analyses focused on unrelated individuals or through investigation of Mendelian forms of dyslipidemia in families^[@R6]^. We previously identified 95 loci associated with blood lipids, accounting for \~10-12% of the total trait variance^[@R4]^ and showed that variants with small effects can point to pathways and therapeutic targets that enable clinically-important changes in blood lipids^[@R4],[@R7]^.

Here, we report on studies of naturally occurring variation in 188,578 European-ancestry individuals and 7,898 non-European ancestry individuals. Our analyses identify 157 loci associated with lipid levels at *P* \< 5×10^−8^, including 62 new loci. Thirty of the 62 loci do not include genes implicated in lipid biology by previous literature. We tested lipid-associated SNPs for association with mRNA expression levels, carried out pathway analyses to uncover relationships between loci, and compared the locations of lipid-associated SNPs with those of genes and other functional elements in the genome. These results provide direction for biological and therapeutic research into risk factors for CAD.

Results {#S2}
=======

Novel loci associated with blood lipid levels {#S3}
---------------------------------------------

We examined subjects of European ancestry, including 94,595 individuals from 23 studies genotyped with GWAS arrays^[@R4]^ and 93,982 individuals from 37 studies genotyped with the Metabochip array^[@R8]^ ([Supplementary Table 1](#SD1){ref-type="supplementary-material"} and [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}). The Metabochip includes variants representing promising loci from our previous GWAS (14,886 SNPs) and from GWAS of other CAD risk factors and related traits (50,459 SNPs), variants from the 1000 Genomes Project^[@R9]^ and focused resequencing^[@R10]^ efforts in 64 previously associated loci (28,923 SNPs), and fine-mapping variants in 181 loci associated with other traits (93,308 SNPs). In cases where Metabochip and GWAS array data were available for the same individuals, we used Metabochip data to ensure key variants were directly genotyped, rather than imputed.

We excluded individuals known to be on lipid lowering medications and evaluated the additive effects of each SNP on blood lipid levels after adjusting for age and sex. Genomic control values^[@R11]^ for the initial meta-analyses were 1.10 -- 1.15, low for a sample of this size, indicating that population stratification should have only a minor impact on our results ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}). After genomic control correction, 157 loci associated with blood lipid levels were identified (*P* \< 5×10^−8^), including 62 new loci ([Tables 1A](#T1){ref-type="table"}-[D](#T4){ref-type="table"}, [Figure 1](#F1){ref-type="fig"}, [Supplementary Tables 2 and 3](#SD1){ref-type="supplementary-material"}). Loci were \>1 Mb apart and nearly independent (r^2^ \< 0.10). Of the 62 novel loci, 24 demonstrated the strongest evidence of association with HDL cholesterol, 15 with LDL cholesterol, 8 with triglyceride levels, and 15 with total cholesterol ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). Several of these loci were validated by a similar extension based on GLGC GWAS results ^[@R12]^.

The effects of newly identified loci were generally smaller than in earlier GWAS ([Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}). For the 62 newly identified variants, trait variance explained in the Framingham offspring were 1.6% for HDL cholesterol, 2.1% for triglycerides, 2.4% for LDL cholesterol, and 2.6% for total cholesterol.

Overlap of genetic discoveries and prior knowledge {#S4}
--------------------------------------------------

To investigate connections between our new loci and known lipid biology, we first catalogued genes within 100 kb of the peak associated SNPs and searched PubMed and OMIM for occurrences of these gene names and their aliases in the context of relevant keywords. After manual curation, we identified at least one strong candidate in 32 of the 62 loci (52%) ([Supplementary Table 4](#SD1){ref-type="supplementary-material"}). For the remaining 30 loci, we found no literature support for the role of a nearby gene on blood lipid levels. This search highlighted genes whose connections to lipid metabolism have been extensively documented in mouse models (such as *VLDLR*^[@R13]^ and *LRPAP1*^[@R13]^) and human cell lines (such as *VIM*^[@R14]^), as well as candidates whose connection to lipid levels is more recent, such as *VEGFA.* For the latter, recent studies of *VEGFB* have suggested that vascular endothelial growth factors have an unexpected role in the targeting of lipids to peripheral tissues^[@R15]^, which we corroborate by associating variants near *VEGFA* with blood triglyceride and HDL levels.

Multiple types of evidence supported several literature candidates ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). For example, *VLDLR* is categorized by Gene Ontology^[@R16]^ in the retinoid × nuclear receptor (RXR) activation pathway, which also includes genes (*APOB, APOE, CYP7A1, APOA1, HNF1A, HNF4A)* in previously implicated loci^[@R4]^. However, since these additional sources of evidence build on overlapping knowledge they are not truly independent.

To estimate the probability of finding ≥32 literature supported candidates after automated search and manual review of results, we repeated our text-mining literature search using 100 permutations of SNPs matched for allele frequency, distance to the nearest gene, and number of linkage disequilibrium proxies. To approximate hand-curation of the text-mining results, we focused on genes implicated by 3 or more publications (25 in observed data, 8.7 on average in control SNP sets, *P* = 8×10^−8^).

Pathway analyses {#S5}
----------------

We performed a gene-set enrichment analysis, using MAGENTA^[@R17]^, to evaluate over-representation of biological pathways among associated loci. Across the 157 loci, MAGENTA identified 71 enriched pathways. These pathways included at least one gene in 20 of our newly identified loci ([Supplementary Table 5](#SD1){ref-type="supplementary-material"}). Examples include *DAGLB* (connected to previously associated loci by genes in the triglyceride lipase activity pathway), *INSIG2* (connected by the cholesterol and steroid metabolic process pathways), *AKR1C4* (connected by the steroid metabolic process and bile acid biosynthesis pathways), *VLDLR* (connected by the retinoic × receptor activation and lipid transport pathways, among others), *PPARA, ABCB11*, and *UGT1A1* (three genes assigned to pathways implicated in activation of nuclear hormone receptors, which play an important role in lipid metabolism through the transcriptional regulation of genes in sterol metabolic pathways^[@R18]^). Among the 16 loci where literature review and pathway analysis both suggested a candidate, the predictions overlapped 14 times ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}; by chance, we expect 6.6 overlapping predictions, *P* = 1×10^−5^).

Protein-protein interactions {#S6}
----------------------------

We assessed evidence for physical interactions between proteins encoded near our associated SNPs using DAPPLE^[@R19]^. We found an excess of direct protein-protein interactions for genes in loci associated with LDL (10 interactions, *P* = 0.0002), HDL (8 interactions, *P* = 0.002), and total cholesterol (6 interactions, *P* = 0.017), but not for triglycerides (2 interactions, *P* = 0.27) ([Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}). Most of the interactions involved genes at known loci (such as the interaction network connecting *PLTP, APOE, APOB*, and *LIPC*) or highlighted the same genes as literature and pathway analyses (such as those connecting *VLDLR, APOE, APOB, CETP*, and *LPL*). Among novel loci, we identified a link between *AKT1* and *GSK3B. GSK3B* has been shown to play a role in energy metabolism^[@R20]^ and its activity is regulated by *AKT1* through phosphorylation^[@R21]^. Literature review also supported a role in blood lipid levels for these two genes.

Regulation of gene expression by associated variants {#S7}
----------------------------------------------------

Many complex trait associated variants act through the regulation of gene expression. We examined whether our 62 novel variants were associated with expression levels of nearby genes in liver, omental fat, or subcutaneous fat. Fifteen were associated with expression of a nearby transcript with *P* \< 5×10^−8^ ([Supplementary Table 6](#SD1){ref-type="supplementary-material"}) and, in seven, the lipid-associated variant was in strong disequilibrium with the strongest expression-quantitative trait locus (eQTL) for the region (r^2^ \> 0.8). In three of these loci, literature search also prioritized candidate genes. In all three, eQTL analysis and literature review identified the same candidate (*DAGLB, SPTLC3*, and *PXK, P* = 0.05). For the remaining four loci (near *RBM5, ADH5, TMEM176A*, and *GPR146*), analysis of expression levels identified candidates that were not supported by literature or pathway analyses.

Coding variation {#S8}
----------------

In some loci where previous coding variant association studies were inconclusive, we now find convincing evidence of association, demonstrating the benefits of the large sample sizes achievable by collaboration. For example, in the *APOH* locus^[@R22]^, our most strongly associated variant is rs1801689 (*APOH* C325G, *P* = 1×10^−11^ for LDL cholesterol). Overall, at 15 of the 62 new loci, there is at least one nonsynonymous variant within 100kb and in strong (r^2^\>0.8) linkage disequilibrium with the index SNP ([Supplementary Table 7](#SD1){ref-type="supplementary-material"})(18 loci with no restrictions on distance). This \~30% overlap between associated loci and coding variation is similar to that in other complex traits^[@R9]^. Unexpectedly, in the 11 loci where a candidate was suggested by literature review and by coding variation, the two coincided seven times (*P* = 0.03 compared to expected chance overlap of 3.8 times); thus, agreement between literature and coding variation was less significant than for eQTL and pathway analysis or protein-protein interactions.

Overlap between association signals and regulators of transcription in liver {#S9}
----------------------------------------------------------------------------

Despite our efforts, 18 of the 62 new loci remain without prioritized candidate genes. The liver is an important hub of lipid biosynthesis and there is evidence that lipid loci might be associated with changes in gene regulation in liver cells^[@R23]^. Using ENCODE data^[@R23]^, we evaluated whether associated SNPs overlapped experimentally annotated functional elements identified in HepG2 cells, a commonly used model of human hepatocytes. To determine significance, we generated 100,000 lists of permuted SNPs, matched for minor allele frequency, distance to the nearest gene, and number of SNPs in r^2^ \> 0.8 (described in Methods). In HepG2 cells, lipid-associated SNPs were enriched in eight of the 15 functional chromatin states defined by Ernst *et al.*^[@R24]^ (*P* \< 1×10^−5^; [Supplementary Table 8](#SD1){ref-type="supplementary-material"}). The strongest enrichment was in regions with "strong enhancer activity" (3.7-fold enrichment, *P* = 2×10^−25^; [Supplementary Table 9](#SD1){ref-type="supplementary-material"}). In the other eight cell types examined by Ernst *et al*., no more than three functional chromatin states showed evidence for enrichment (and, when present, enrichment was weaker).

We proceeded to investigate the overlap between lipid loci and functional marks in HepG2 cells in more detail ([Supplementary Table 9](#SD1){ref-type="supplementary-material"}). Notable regulatory elements showing significant overlap with lipid loci included histone marks associated with active regulatory regions (H3K27ac, *P* = 3×10^−20^; H3K9ac, *P* = 3×10^−22^), promoters (H3K4me3, *P* = 2×10^−15^, H3K4me2, P = 8×10^−12^), transcribed regions (H3K36me3, *P* = 4×10^−14^), indicators of open chromatin (FAIRE, *P* = 5×10^−9^; DNase, *P* = 2×10^−4^), and regions that interact with transcription factors HNF4A (*P* = 6×10^−10^) and CEBP/B (*P* = 1×10^−5^). Overall, 56 of our 62 new loci contained at least one SNP that overlaps a functional mark^[@R24]^ and/or chromatin state^[@R23]^ highlighted in [Supplementary Table 9](#SD1){ref-type="supplementary-material"}, including all but 3 of the loci where no candidates were suggested by literature review or analyses of pathways, coding variation, or gene expression ([Supplementary Table 10](#SD1){ref-type="supplementary-material"}).

Initial fine-mapping of 65 lipid-associated loci {#S10}
------------------------------------------------

Previous fine-mapping of five LDL-associated lipid loci found that variants showing the strongest association were often substantially different in frequency and effect size from those identified in GWAS^[@R10]^. Metabochip genotypes enabled us to carry out an initial fine-mapping analysis for 65 loci: 60 selected for fine-mapping based on our previous study^[@R4]^ and 5 nominated for fine-mapping because of association to other traits.

For each of these loci, we identified the most strongly associated Metabochip variant and evaluated whether it (a) reached genome-wide significant evidence for association (to avoid chance fluctuations in regions where the signal was relatively weak) and (b) was different from the GWAS index SNP in terms of frequency and effect size (operationalized to r^2^ \< 0.8 with the GWAS index SNP). In the European samples, fine-mapping identified eight loci where the fine-mapping signal was clearly different from the GWAS signal ([Supplementary Table 11](#SD1){ref-type="supplementary-material"}). The two largest differences were at the loci near *PCSK9* (top GWAS variant with minor allele frequency f = 0.24 and *P* = 9×10^−24^; fine-mapping variant with f = 0.03, *P* = 2×10^−136^) and *APOE* (GWAS variant f = 0.20, *P* = 3×10^−44^, fine-mapping variant f = 0.07, *P* = 3×10^−651^), consistent with Sanna *et al*^10^. Large differences were also observed near *LRP4* (GWAS f = 0.17, *P* = 8×10^−14^; fine-mapping f = 0.35, *P* = 1×10^−26^), *IGF2R* (GWAS f = 0.16, *P* = 7×10^−9^; fine-mapping f = 0.37, *P* = 2×10^−13^), *NPC1L1* (GWAS f = 0.27, *P* = 2×10^−5^; fine-mapping f = 0.24, *P* = 1×10^−12^), *ST3GAL4* (GWAS f = 0.26, *P* = 2×10^−6^; fine-mapping f = 0.07, *P* = 6×10^−11^), *MED1* (GWAS f = 0.37, *P* = 3×10^−5^; fine-mapping f = 0.24, *P* = 2×10^−10^), and *COBLL1* (GWAS f = 0.12, *P* = 2×10^−6^; fine-mapping f = 0.11, *P* = 6×10^−9^). Thus, although the large changes observed by Sanna *et al*^[@R10]^ after fine-mapping are by no means unique, they are not typical. Except for the R46L variant in *PCSK9*, the variants showing strongest association in fine-mapped loci all had minor allele frequency \> .05.

We also attempted fine-mapping in African (N=3,263), East Asian (N=1,771), and South Asian (N=4,901) ancestry samples. Despite comparatively small samples, ancestry-specific analyses identified SNPs clearly distinct from the original GWAS variant in five loci ([Supplementary Table 11](#SD1){ref-type="supplementary-material"}). These were: *APOE*, consistent with European ancestry analyses above; three loci where differences in linkage disequilibrium between populations enabled fine-mapping in African (*SORT1, LDLR*) or East Asian (*APOA5*) ancestry samples; and *CETP*, where an African-specific variant was present. For *CETP, SORT1*, and *APOA5*, results are consistent with other fine-mapping and functional studies^[@R7],[@R7],[@R25],[@R26]^.

Association of lipid loci with metabolic and cardiovascular traits {#S11}
------------------------------------------------------------------

To evaluate the role of the 157 loci identified here on related traits, we evaluated the most strongly associated SNPs for each locus in genetic studies of coronary artery disease (CAD, N=114,590 including 37,653 cases)^[@R27],[@R28]^, type 2 diabetes (T2D, N=47,117 including 8,130 cases)^[@R29]^, body mass index (BMI, N=123,865 individuals)^[@R30]^ and waist-hip ratio (WHR, N=77,167 individuals)^[@R31]^, systolic and diastolic blood pressure (SBP and DBP, N=69,395 individuals)^[@R32]^, and fasting glucose (N=46,186 non-diabetics)^[@R33]^. We observed an excess of SNPs nominally associated (*P* \< 0.05) with all these traits: a 5.1 fold excess for CAD (40 nominally significant loci, *P* = 2×10^−19^), a 4.1 fold excess for BMI (32 loci, *P* = 1×10^−11^), 3.7 fold excesses for DBP (29 loci, *P* = 1×10^−9^), a 3.4 fold excess for WHR (27 loci, *P* = 1×10^−9^), a 2.5 fold excess for SBP (20 loci, *P* = 1×10^−4^), a 2.3 fold excess for T2D (18 loci, *P* = 0.001), and a 2.2 fold excess for fasting glucose (17 loci, *P* = 3×10^−3^) ([Supplementary Table 12](#SD1){ref-type="supplementary-material"}). Interestingly, among the novel loci, we observed greater overlap with BMI, SBP, and DBP (9 overlapping loci each) than with CAD (8 overlapping loci). Among new loci, the two SNPs showing strongest association to CAD map near *RBM5* (rs2013208, *P*~HDL~ = 9×10^−12^, *P*~CAD~ = 7×10^−5^) and *CMTM6* (rs7640978, *P*~LDL~ = 1×10^−8^, *P*~CAD~ = 4×10^−4^).

We tested whether the LDL-, total cholesterol- or triglyceride-increasing allele, or HDL-decreasing allele was associated with increased risk of cardiovascular disease or related metabolic outcomes; the direction of effect of each locus was categorized according to the primary association signal at the locus, as in [Tables 1A](#T1){ref-type="table"}-[D](#T4){ref-type="table"}. We observed association with increased CAD risk (104/149, *P* = 1×10^−6^), SBP (96/155, *P* = 2.7×10^−3^) and WHR adjusted for BMI (92/154, *P* = 0.019). There were many instances where a single locus was associated with many traits. These included variants near *FTO*, consistent with previous reports^[@R34]^; near *VEGFA* (associated with triglyceride levels, CAD, T2D, SBP, and DBP), near *SLC39A8* (associated with HDL cholesterol, BMI, SBP, and DBP), and near *MIR581* (associated with HDL cholesterol, BMI, T2D, and DBP). In some cases, like *FTO*, a strong association with BMI or another phenotype generates weaker association signals for other metabolic traits^[@R34]^. In other cases, like *SORT1*, a primary effect on lipid levels may mediate secondary association with other traits, like CAD^[@R7]^.

Association of individual lipids with coronary artery disease {#S12}
-------------------------------------------------------------

Epidemiological studies consistently show high total cholesterol and LDL cholesterol levels are associated with increased risk of CAD, whereas high HDL cholesterol levels are associated with reduced risk of CAD^[@R35]^. In genetic studies, the connection between LDL cholesterol and CAD is clear, whereas the results for HDL cholesterol levels are more equivocal^[@R36]-[@R38]^. In our data, trait increasing alleles at the loci showing strongest association with LDL cholesterol (31 loci), triglycerides (30 loci), or total cholesterol (38 loci) were associated with increased risk of CAD (*P* = 2×10^−12^, *P* = 2×10^−16^, and *P* = 0.006). Conversely, trait decreasing alleles at loci showing the strongest association with HDL cholesterol (64 loci), were associated with increased CAD risk with *P* = 0.02. When we focused on loci uniquely associated with LDL cholesterol (12 loci where *P* \> .05 for other lipids), triglycerides (6 loci), or HDL cholesterol (14 loci), only the LDL association remained significant (*P* = 0.03).

To better explore how associations with individual lipid levels related to CAD risk, we used linear regression to test whether association with lipid levels could predict impact on CAD risk. In this analysis, the effect on CAD of 149 lipid loci (CAD results were not available for 8 SNPs) was correlated with LDL (Pearson r=0.74, *P* = 7×10^−6^) and triglyceride (Pearson r=0.46, *P* = 0.02) effect sizes, but not HDL effect sizes (Pearson r=−9×10^−4^, *P* = 0.99; [Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}). Since most variants affect multiple lipid fractions ([Figure 1](#F1){ref-type="fig"}), dissecting the relationship between lipid level and CAD effects requires multivariate analysis. In a companion manuscript, we use multivariate analysis and detailed examination of triglyceride associated loci to show that increased LDL and triglyceride levels, but not HDL, appear causally related to CAD risk.

Evidence for additional loci, not yet reaching genome-wide significance {#S13}
-----------------------------------------------------------------------

To evaluate evidence for loci not yet reaching genome-wide significance, we compared direction of effect in GWAS and Metabochip analyses of non-overlapping samples, outside the 157 genome-wide significant loci. Among independent variants (r^2^ \< 0.1) with *P* \< 0.1 in the GWAS-only analysis, a significant excess were concordant in direction of effect for HDL (62.9% in 1,847 SNPs, *P* \< 10^−16^), LDL (58.6% of 1,730 SNPs, *P* \< 10^−16^), triglyceride levels (59.1% of 1,783 SNPs, *P* \< 10^−16^), and total cholesterol (61.0% of 1,904 SNPs, *P* \< 10^−16^), suggesting many additional loci to be discovered in future studies.

Discussion {#S14}
==========

Molecular understanding of the genes and pathways that modify blood lipid levels in humans will facilitate the design of new therapies for cardiovascular and metabolic disease. This understanding can be gained from studies of model organisms, *in vitro* experiments, bioinformatic analyses, and human genetic studies. Here, we demonstrate association between blood lipid levels and 62 new loci, bringing the total number of lipid-associated loci to 157 (See [Tables 1A](#T1){ref-type="table"}-[D](#T4){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}). All but one of the loci identified here include protein-coding genes within 100 kb of the SNP showing strongest association. While 38 of the 62 new loci include genes whose role in blood lipid levels is supported by literature review or analysis of curated pathway databases, the remainder includes only genes whose role on blood lipid levels has not been documented.

In total, there are 240 genes within 100 kb of one of our 62 new lipid-associated loci -- providing a daunting challenge for future functional studies. Prioritizing on the basis of literature review, pathway analysis, regulation of mRNA expression levels, and protein altering variants suggests that 70 genes in 44 of the 62 new loci might be the focus of the first round of functional studies (summarized in [Supplementary Table 2](#SD1){ref-type="supplementary-material"}). While we found significant overlap, different sources of prioritization sometimes disagreed. This result suggests that truly understanding causality will be very challenging. The Supplementary Note includes an interpreted digest of genes highlighted by our study. Clearly, a range of approaches will be needed to follow-up these findings. To illustrate possibilities, consider U. S. Patent Application \#20,090,036,394 disclosing that, in the mouse, knockout of *Gpr146* modifies blood lipid levels. Here, we show that variants near the human homologue of this gene, *GPR146*, are associated with levels of total cholesterol -- providing an added incentive for studies of GPR146 inhibitors in humans. *GPR146* encodes a G-protein coupled receptor -- an attractive pharmaceutical target -- so it is tempting to speculate that, one day, pharmaceutical inhibition of GPR146 may modify cholesterol levels and reduce risk of heart disease.

Each locus typically includes many strongly associated (and potentially causal) variants. Our fine-mapping results illustrate how genetic analysis of large samples and individuals of diverse ancestry can help focus the search for causal variants. In our fine-mapping analysis of 65 lipid-associated loci, we were able to separate the strongest signal in a region from the prior GWAS signal in 12 instances. In three of these 12 instances, fine-mapping was enabled by analysis of a few thousand African or East Asian ancestry individuals, whereas in the remaining instances, fine-mapping was possible through examination of nearly 100,000 European ancestry samples. A more detailed fine-mapping exercise, including imputation of variants from emerging very large reference panels, may help refine the location of additional signals.

Lipid-associated loci were strongly associated with CAD, T2D, BMI, SBP, and DBP. In univariate analyses, we found that impact on LDL and triglycerides all predicted association with CAD, but HDL did not. In a more detailed multivariate investigation, a companion manuscript shows that our data is consistent with the hypothesis that both LDL and triglycerides, but not HDL, are causally related to CAD risk. HDL, LDL, and triglycerides levels summarize aggregate levels of different lipid particles, each with potentially distinct consequences for CAD risk. We evaluated association of our loci with lipid subfractions in 2,900 individuals from the Framingham Heart Study ([Supplementary Table 13](#SD1){ref-type="supplementary-material"}, [Supplementary Fig. 7](#SD1){ref-type="supplementary-material"}) and with sphingolipids, which are components of lipid membranes in cells, in 4,034 individuals from five samples of European ancestry^[@R39]^ ([Supplementary Table 14](#SD1){ref-type="supplementary-material"}). The results suggest HDL-associated variants can have a markedly different impact on these sub-phenotypes. For example, among HDL loci, variants near *LIPC* were strongly associated with plasmalogen levels (*P* \< 10^−40^), variants near *ABCA1* were associated with sphingomyelin levels (*P* \< 10^−5^), and variants near *CETP* -- which show the strongest association with HDL cholesterol overall -- were associated with neither of these. Detailed genetic dissection of these sub-phenotypes in larger samples, could lead to functional groupings of HDL-associated variants that reconcile the results of genetic studies (which show no clear connection between HDL cholesterol-associated variants and CAD risk) and epidemiologic studies (which show clear association between plasma HDL levels and CAD risk).

In summary, we report the largest genetic association study of blood lipid levels yet conducted. The large number of loci identified, the many candidate genes they contain, and the diverse proteins they encode generate new leads and insights into lipid biology. It is our hope that the next round of genetic studies will build on these results, using new sequencing, genotyping, and imputation technologies to examine rare loss-of-function alleles and other variants of clear functional impact to accelerate the translation of these leads into mechanistic insights and improved treatments for CAD.

Online Methods {#S15}
==============

Samples studied {#S16}
---------------

We collected summary statistics for Metabochip SNPs from 45 studies. Among these, 37 studies consisted primarily of individuals of European ancestry (see [Supplementary Table 1](#SD1){ref-type="supplementary-material"} and [Supplementary Note](#SD1){ref-type="supplementary-material"} for details), including both population-based studies and case-control studies of CAD and T2D. Another 8 studies consisted primarily of individuals with non-European ancestry: two studies of South Asian descent, AIDHS/SDS (N=1,516) and PROMIS (N=3,385); two studies of East Asian descent, CLHNS (N=1,771) and TAI-CHI (N=7044); and five studies of recent African ancestry, MRC/UVRI GPC (N=1,687) from Uganda, SEY (N=426) from the Caribbean, and FBPP (N=1,614, TG results unavailable), GXE (N=397), and SPT (N=838) from the United States (more details in [Supplementary Table 1](#SD1){ref-type="supplementary-material"} and [Supplementary Note](#SD1){ref-type="supplementary-material"}).

Genotyping {#S17}
----------

We genotyped 196,710 genetic variants prioritized on the basis of prior GWAS for cardiovascular and metabolic phenotypes using the Illumina iSelect Metabochip^[@R8]^ genotyping array. To design the Metabochip, we used our previous GWAS of \~100,000 individuals^[@R4]^ to prioritize 5,023 SNPs for HDL cholesterol, 5,055 for LDL cholesterol, 5,056 for triglycerides, and 938 for total cholesterol. These independent SNPs represent most loci with *P* \< .005 in our original GWAS for HDL cholesterol, LDL cholesterol and triglycerides and with *P* \< .0005 for total cholesterol. An additional 28,923 SNPs were selected for fine-mapping of 65 previously identified lipid loci. The Metabochip also included 50,459 SNPs prioritized based on GWAS of non-lipid traits and 93,308 SNPs selected for fine-mapping of loci associated with non-lipid traits (5 of these loci were associated with blood lipids by the analyses described here).

Phenotypes {#S18}
----------

Blood lipid levels were typically measured after \> 8 hours of fasting. Individuals known to be on lipid-lowering medication were excluded when possible. LDL cholesterol levels were directly measured in 10 studies (24% of total study individuals) and estimated using the Friedewald formula^[@R40]^ in the remaining studies. Trait residuals within each study cohort were adjusted for age, age^[@R2]^, and sex, and then quantile normalized. Explicit adjustments for population structure using principal component^[@R41]^ or mixed model approaches^[@R42]^ were carried out in 24 studies (35% of individuals); all studies were adjusted using genomic control prior to meta-analysis^[@R11]^. In studies ascertained on diabetes or CVD status, cases and controls were analyzed separately ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). All meta-analyses were limited to a single ancestral group (e.g. European only).

Primary statistical analysis {#S19}
----------------------------

Individual SNP association tests were performed using linear regression with the inverse normal transformed trait values as the dependent variable and the expected allele count for each individual as the independent variable. These analyses were performed using PLINK (26 samples, 53% of the total number of individuals), SNPTEST (4 samples, 20% of individuals), EMMAX (9 samples, 14% of individuals), Merlin (4 samples, 9% of individuals), GENABEL (1 sample, 3% of individuals), and MMAP (1 sample, 1% of individuals) ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}).

Meta-analysis {#S20}
-------------

Meta-analysis was performed using the Stouffer method^[@R43],[@R44]^, with weights proportional to the square root of the sample size for each sample. To correct for inflated test statistics due to potential population stratification, we first applied genomic control to each sample and then repeated the procedure with initial meta-analysis results. For GWAS samples, we used all available SNPs when estimating the median test statistic and inflation factor λ. For Metabochip samples, we used a subset of SNPs (N = 7,168) that had *P*-values \> 0.50 for all lipid traits in the original GWAS, expecting that the majority of these would not be associated with lipids and would behave as null variants in the Metabochip samples. Signals were considered to be novel if they reached a *P*-value \< 5×10^−8^ in the combined GWAS and Metabochip meta-analysis and were \>1 Mb away from the nearest previously described lipid locus and other novel loci. We used only European samples for the discovery of novel genome-wide significant loci. The non-European samples were meta-analyzed and examined only for fine-mapping analyses.

Quality control {#S21}
---------------

To flag potentially erroneous analyses, we carried out a series of quality control steps. Average standard errors for association statistics from each study were plotted against study sample size to identify outlier studies. We inspected allele frequencies to ensure all analyses used the same strand assignment of alleles. We evaluated whether reported statistics and allelic effects were consistent with published findings for known loci. Genomic control values for study specific analyses were inspected, and all were \<1.20. Finally, within each study, we excluded variants for which the minor allele was observed \<7 times.

Proportion of trait variance explained {#S22}
--------------------------------------

We estimated the increase in trait variance explained by novel loci in the Framingham cohort (N=7,132) using three models for each trait-residual: 1) lead and secondary SNPs from the previously published loci^[@R4]^ and 2) previously published lipid loci plus newly reported loci; and 3) newly reported loci. We regressed lipid residuals on these sets of SNPs using the lme kinship package in R.

Initial automated review of the published literature {#S23}
----------------------------------------------------

An initial list of candidates within each locus was generated with Snipper (<http://csg.sph.umich.edu/boehnke/snipper/>) and then subjected to manual review. For each locus, Snipper first generates a list of nearby genes and then checks for the co-occurrence of the corresponding gene names and selected search terms ("cholesterol", "lipids", "HDL", "LDL", or "triglycerides") in published literature and OMIM. We supplemented this approach with traditional literature searches using PubMed and Google.

Generating permuted sets of non-associated SNPs {#S24}
-----------------------------------------------

To estimate the expected chance overlap between literature searches and our loci, we generated lists of permuted SNPs. To generate these lists, we first identified all non-associated lipid SNPs (P \> 0.10 for any of the 4 lipid traits) and created bins based on 3 statistics: minor allele frequency, distance to the nearest gene, and number of SNPs with r^2^ \> 0.8. For each index SNP, we identified 500 non lipid-associated SNPs that fell within the same 3 bins and randomly selected one SNP for each permuted list.

Pathway analyses {#S25}
----------------

To investigate if lipid-associated variants overlapped previously annotated pathways, we used gene set enrichment analysis (GSEA), as implemented in MAGENTA^[@R17]^ using the meta-analysis of all studies, including GWAS and Metabochip SNPs. Briefly, MAGENTA first assigns SNPs to a given gene when within 110 kb upstream or 40 kb downstream of transcript boundaries. The most significant SNP *P*-value within this interval is then adjusted for confounders (gene size, marker density, LD) to create a gene association score. When the same SNP is assigned to multiple genes, only the gene with the lowest score is kept for downstream analyses. Subsequently, MAGENTA attaches pathway terms to each gene using several annotation resources, including GO, PANTHER, Ingenuity, and KEGG. Finally, the genes are ranked on their gene association score, and a modified GSEA test is used to test the null hypothesis that all gene score ranks above a given rank cutoff are randomly distributed with regard to a given pathway term (and compared to multiple randomly sampled gene sets of identical size). We evaluated enrichment by using a rank cutoff of 5% of the total number of genes. A minimum of 10,000 gene set permutations were performed, and up to 1,000,000 permutations for GSEA *P*-values below 1×10^−4^.

We used the Disease Association Protein--Protein Link Evaluator package (DAPPLE; <http://www.broadinstitute.org/mpg/dapple/dapple.php>) to examine evidence for protein-protein interaction networks connecting genes across different lipid loci. This analysis included the 62 novel loci as well as the 95 previously known loci; we focus our discussion on pathways that included one or more genes from novel loci.

Cis-expression quantitative trait locus analysis {#S26}
------------------------------------------------

To determine whether lipid-associated SNPs might act as *cis*-regulators of nearby genes, we examined association with expression levels of 39,280 transcripts in 960 human liver samples, 741 human omental fat samples, and 609 human subcutaneous fat samples. Tissue samples were collected postmortem or during surgical resection from donors; tissue collection, DNA and RNA isolation, expression profiling, and genotyping were performed as described^[@R45]^. MACH was used to obtain imputed genotypes for \~2.6 million SNPs in the HapMap release 22 for each of the samples. We examined the correlation between each of the 62 new index SNPs and all transcripts within 500 kb of the SNP position, performing association analyses as previously described^[@R46]^.

Functional annotation of associated variants {#S27}
--------------------------------------------

We attempted to identify lipid-associated SNPs that fall in important regulatory domains. We initially created a list of all potentially causal variants by selecting index SNPs at loci identified in this study or in Teslovich *et al*^[@R4]^. We then selected any variant in strong linkage disequilibrium (r^2^ \> 0.8 from 1000 Genomes or HapMap) with each index SNP. We compared the position of the index SNPs and their proxies to previously described functional marks^[@R23],[@R24]^. To assess the expected overlap with functional marks, we created 100,000 permuted sets of non-associated SNPs (see above) and evaluated permuted SNP lists for overlap with functional domains. We estimated a *P*-value for each functional domain as the proportion of permuted sets with an equal or greater number of loci overlapping functional domains (for large *P*-values). For small *P*-values we used a normal approximation to the empirical overlap distribution to estimate *P*-values.

Association with lipid subfractions {#S28}
-----------------------------------

Lipoprotein fractions for Women's Genome Health Study (WGHS) samples (N = 23170) were measured using the LipoProtein-II assay (Liposcience Inc. Raleigh, NC) and Framingham Heart Study Offspring samples (N = 2900) were measured with the LipoProtein-I assay (Liposcience Inc. Raleigh, NC)^[@R47]^. Additional information on sub-fraction measurements can be found in [Supplementary Fig. 7](#SD1){ref-type="supplementary-material"}. Log transformations were used for non-normalized traits. All models were adjusted for age, sex, and PCs. The genetic association analysis of WGHS used SNP genotypes imputed from the HapMap r22 CEU reference panel using MACH. 16,730 out of 23,170 WGHS participants were fasting for 8 hours prior to blood draw (72.2%).
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======================
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![Overlap between loci associated with different lipid traits\
This Venn Diagram illustrates the number of loci that show association with multiple lipid traits. The number of loci primarily associated with only one trait is listed in parentheses after the trait name and the locus name is listed below in italics. Loci that show association with two or more traits are shown in the appropriate section.](nihms-524703-f0001){#F1}

###### Novel Loci Primarily Associated with HDL Cholesterol Obtained from Joint GWAS and Metabochip Meta-analysis

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Locus            MarkerName   Chr   hg19\           Associated trait(s)                        MAF   Minor/major\   Effect of A1      Joint N\      Joint *P*-value
                                      Position (Mb)                                                    Allele                           (in 1000s)    
  ---------------- ------------ ----- --------------- ------------------------------------------ ----- -------------- ----------------- ------------- ------------------------------
  *PIGV-NR0B2*     rs12748152   1     27.14           HDL, LDL, TG                               .09   T/C            −.051/.050/.037   187/173/178   1×10^−15^/3×10^−12^/1×10^−9^

  *HDGF-PMVK*      rs12145743   1     156.70          HDL                                        .34   G/T            .020              181           2×10^−8^

  *ANGPTL1*        rs4650994    1     178.52          HDL                                        .49   G/A            .021              187           7×10^−9^

  *CPS1*           rs1047891    2     211.54          HDL                                        .33   A/C            −.027             182           9×10^−10^

  *ATG7*           rs2606736    3     11.40           HDL                                        .39   C/T            .025              129           5×10^−8^

  *SETD2*          rs2290547    3     47.06           HDL                                        .20   A/G            −.030             187           4×10^−9^

  *RBM5*           rs2013208    3     50.13           HDL                                        .50   T/C            .025              170           9×10^−12^

  *STAB1*          rs13326165   3     52.53           HDL                                        .21   A/G            .029              187           9×10^−11^

  *GSK3B*          rs6805251    3     119.56          HDL                                        .39   T/C            .020              186           1×10^−8^

  *C4orf52*        rs10019888   4     26.06           HDL                                        .18   G/A            −.027             187           5×10^−8^

  *FAM13A*         rs3822072    4     89.74           HDL                                        .46   A/G            −.025             187           4×10^−12^

  *ADH5*           rs2602836    4     100.01          HDL                                        .44   A/G            .019              187           5×10^−8^

  *RSPO3*          rs1936800    6     127.44          HDL, TG^[a](#TFN1){ref-type="table-fn"}^   .49   C/T            .020/−.020        187/168       3×10^−10^/3×10^−8^

  *DAGLB*          rs702485     7     6.45            HDL                                        .45   G/A            .024              187           7×10^−12^

  *SNX13*          rs4142995    7     17.92           HDL                                        .38   T/G            −.026             165           9×10^−12^

  *IKZF1*          rs4917014    7     50.31           HDL                                        .32   G/T            .022              187           1×10^−8^

  *TMEM176A*       rs17173637   7     150.53          HDL                                        .12   C/T            −.036             184           2×10^−8^

  *MARCH8-ALOX5*   rs970548     10    46.01           HDL, TC                                    .26   C/A            .026/−.026        187/187       2×10^−10^/8×10^−9^

  *OR4C46*         rs11246602   11    51.51           HDL                                        .15   C/T            .034              176           2×10^−10^

  *KAT5*           rs12801636   11    65.39           HDL                                        .23   A/G            .024              187           3×10^−8^

  *MOGAT2-DGAT2*   rs499974     11    75.46           HDL                                        .19   A/C            −.026             187           1×10^−8^

  *ZBTB42-AKT1*    rs4983559    14    105.28          HDL                                        .40   G/A            .020              184           1×10^−8^

  *FTO*            rs1121980    16    53.81           HDL, TG                                    .43   A/G            −.020/−.021       186/155       7×10^−9^/3×10^−8^

  *HAS1*           rs17695224   19    52.32           HDL                                        .26   A/G            −.029             185           2×10^−13^
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Chr, chromosome;MAF, minor allele frequency; A1, minor allele; A2, major allele.Effect sizes are given with respect to the minor allele (A1) in SD units. For loci associated with two or more traits at genome-wide significance, the trait corresponding to the strongest *P*-value is listed first. At one locus, the secondary trait was most strongly associated with a different SNP:

rs719726 (within 1Mb of rs1936800, r^2^ = 0.74).

###### Novel Loci Primarily Associated with LDL Cholesterol Obtained from Joint GWAS and Metabochip Meta-analysis

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Locus           MarkerName   Chr   hg19\       Associated\                                    MAF   Minor/major\   Effect of A1     Joint N\      Joint *P*-value
                                     Position\   trait(s)                                             Allele                          (in 1000s)    
                                     (Mb)                                                                                                           
  --------------- ------------ ----- ----------- ---------------------------------------------- ----- -------------- ---------------- ------------- --------------------------------
  *ANXA9-CERS2*   rs267733     1     150.96      LDL                                            .16   G/A            −.033            165           5×10^−9^

  *EHBP1*         rs2710642    2     63.15       LDL                                            .35   G/A            −.024            173           6×10^−9^

  *INSIG2*        rs10490626   2     118.84      LDL, TC^[b](#TFN2){ref-type="table-fn"}^       .08   A/G            −.051/.042       173/184       2×10^−12^/6×10^−9^

  *LOC84931*      rs2030746    2     121.31      LDL, TC                                        .40   T/C            .021/.020        173/187       9×10^−9^/4×10^−8^

  *FN1*           rs1250229    2     216.30      LDL                                            .27   T/C            −.024            173           3×10^−8^

  *CMTM6*         rs7640978    3     32.53       LDL, TC                                        .09   T/C            −.039/−.038      172/186       1×10^−8^

  *ACAD11*        rs17404153   3     132.16      LDL, HDL^[c](#TFN3){ref-type="table-fn"}^      .14   T/G            −.034/.028       172/187       2×10^−9^/5×10^−9^

  *CSNK1G3*       rs4530754    5     122.86      LDL, TC                                        .46   G/A            −.028/−.023      173/187       4×10^−12^/2×10^−9^

  *MIR148A*       rs4722551    7     25.99       LDL, TG^[d](#TFN4){ref-type="table-fn"}^, TC   .20   C/T            .039/.029/.023   173/187/178   4×10^−14^/9×10^−11^/7.0×10^−9^

  *SOX17*         rs10102164   8     55.42       LDL, TC                                        .21   A/G            .032/.030        173/187       4×10^−11^/5×10^−11^

  *BRCA2*         rs4942486    13    32.95       LDL                                            .48   T/C            .024             172           2×10^−11^

  *APOH-PRXCA*    rs1801689    17    64.21       LDL                                            .04   C/A            .103             111           1×10^−11^

  *SPTLC3*        rs364585     20    12.96       LDL                                            .38   A/G            −.025            172           4×10^−10^

  *SNX5*          rs2328223    20    17.85       LDL                                            .21   C/A            .03              171           6×10^−9^

  *MTMR3*         rs5763662    22    30.38       LDL                                            .04   T/C            .077             163           1×10^−8^
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Chr, chromosome;MAF, minor allele frequency; A1, minor allele; A2, major allele.Effect sizes are given with respect to the minor allele (A1) in SD units. For loci associated with two or more traits at genome-wide significance, the trait corresponding to the strongest *P*-value is listed first. At three loci, secondary traits were most strongly associated with different SNPs.

rs17526895 (within 1Mb of rs10490626, r^2^ = 0.98);

rs13076253 (within 1Mb of rs17404153, r^2^ = 0.00);

rs4719841 (within 1Mb of rs4722551, r^2^ = 0.10).

###### Novel Loci Primarily Associated with Total Cholesterol Obtained from Joint GWAS and Metabochip Meta-analysis

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Locus          MarkerName   Chr   hg19\       Associated\                                MAF   Minor/major\   Effect of A1    Joint N\     Joint *P*-value
                                    Position\   trait(s)                                         Allele                         (in 1000s)   
                                    (Mb)                                                                                                     
  -------------- ------------ ----- ----------- ------------------------------------------ ----- -------------- --------------- ------------ ---------------------
  *ASAP3*        rs1077514    1     23.77       TC                                         .15   C/T            −0.03           184          6×10^−9^

  *ABCB11*       rs2287623    2     169.83      TC                                         .41   G/A            0.027           184          4×10^−12^

  *FAM117B*      rs11694172   2     203.53      TC                                         .25   G/A            0.028           187          2×10^−9^

  *UGT1A1*       rs11563251   2     234.68      TC, LDL                                    .12   T/C            0.037/0.034     187/173      1×10^−9^/5×10^−8^

  *PXK*          rs13315871   3     58.38       TC                                         .10   A/G            −0.036          187          4×10^−8^

  *KCNK17*       rs2758886    6     39.25       TC                                         .30   A/G            0.023           187          3×10^−8^

  *HBS1L*        rs9376090    6     135.41      TC                                         .28   T/C            −0.025          187          3×10^−9^

  *GPR146*       rs1997243    7     1.08        TC                                         .16   G/A            0.033           183          3×10^−10^

  *VLDLR*        rs3780181    9     2.64        TC, LDL                                    .08   G/A            −0.044/−0.044   186/172      7×10^−10^/2×10^−9^

  *VIM-CUBN*     rs10904908   10    17.26       TC                                         .43   G/A            0.025           187          3×10^−11^

  *PHLDB1*       rs11603023   11    118.49      TC                                         .42   T/C            0.022           187          1×10^−8^

  *PHC1-A2ML1*   rs4883201    12    9.08        TC                                         .12   G/A            −0.035          187          2×10^−9^

  *DLG4*         rs314253     17    7.09        TC, LDL                                    .37   C/T            −0.023/−0.024   184/170      3×10^−10^/3×10^−10^

  *TOM1*         rs138777     22    35.71       TC                                         .36   A/G            0.021           185          5×10^−8^

  *PPARA*        rs4253772    22    46.63       TC, LDL^[e](#TFN5){ref-type="table-fn"}^   .11   T/C            0.032/−0.031    185/171      1×10^−8^/3×10^−8^
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------

Chr, chromosome;MAF, minor allele frequency; A1, minor allele; A2, major allele.Effect sizes are given with respect to the minor allele (A1) in SD units. For loci associated with two or more traits at genome-wide significance, the trait corresponding to the strongest *P*-value is listed first. At one locus, the secondary trait was most strongly associated with a different SNP:

rs4253776 (within 1Mb of rs4253772, r^2^ = 0.95).

###### Novel Loci Primarily Associated with Triglycerides Obtained from Joint GWAS and Metabochip Meta-analysis

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Locus      MarkerName   Chr   hg19\       Associated\                                                                    MAF   Minor/major\   Effect of A1     Joint N\      Joint P-value
                                Position\   trait(s)                                                                             Allele                          (in 1000s)    
                                (Mb)                                                                                                                                           
  ---------- ------------ ----- ----------- ------------------------------------------------------------------------------ ----- -------------- ---------------- ------------- ------------------------------
  *LRPAP1*   rs6831256    4     3.47        TG, TC^[f](#TFN6){ref-type="table-fn"}^,LDL^[f](#TFN6){ref-type="table-fn"}^   .42   G/A            0.026/−0.022/−   177/173/187   2×10^−12^/1×10^−10^/2×10^−8^

                                                                                                                                                0.025                          

  *VEGFA*    rs998584     6     43.76       TG, HDL                                                                        .49   A/C            0.029/−0.026     175/184       3×10^−15^/2×10^−11^

  *MET*      rs38855      7     116.36      TG                                                                             .47   G/A            −0.019           178           2×10^−8^

  *AKR1C4*   rs1832007    10    5.25        TG                                                                             .18   G/A            −0.033           178           2×10^−12^

  *PDXDC1*   rs3198697    16    15.13       TG                                                                             .43   T/C            −0.020           176           2×10^−8^

  *MPP3*     rs8077889    17    41.88       TG                                                                             .22   C/A            0.025            176           1×10^−8^

  *INSR*     rs7248104    19    7.22        TG                                                                             .42   A/G            −0.022           176           5×10^−10^

  *PEPD*     rs731839     19    33.90       TG, HDL                                                                        .35   G/A            0.022/−0.022     176/185       3×10^−9^/3×10^−9^
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Chr, chromosome;MAF, minor allele frequency; A1, minor allele; A2, major allele.Effect sizes are given with respect to the minor allele (A1) in SD units. For loci associated with two or more traits at genome-wide significance, the trait corresponding to the strongest *P*-value is listed first. At one locus, secondary traits were most strongly associated with a different SNP:

rs6818397 (within 1 Mb of rs6831256, r^2^ = 0.18).
